Artificial intelligence for screening nanomaterials, and enhanced characterization methods are needed to make nanomedicine more successful

Inorganic nanomaterial-based carriers may perform combinatorial gene-chemotherapy or gene-immunotherapy. Nanomedicines' fate in the human body has yet to be fully described. Limitations in large-scale manufacture and animal models have limited this nanomedicine's practical adoption. Mass nanomaterials with consistent quality and properties are required for therapeutic usage. Another obstacle to clinical nanomedicine translation is a paucity of understanding regarding the interactions between nanoparticles and animal models. The study indicated that gene therapy, along with other treatment approaches, was a successful anticancer treatment. Inorganic nanoparticles can also employ their optoelectronic or magnetic properties to capture external energy for radiotherapy and hyperthermal applications. Nanomedicines for clinical application should be supplied at higher dosages, maintain longer periods of blood circulation, penetrate stronger biological barriers, and detect human-specific biomarkers to be successful in human bodies. To create inorganic nanomaterial-mediated combinatorial gene therapy, more technical advancements are needed in many other areas. Nucleic acid designs, artificial intelligence (AI) for screening nanomaterials, and enhanced characterization methods are needed to make nanomedicine more successful. AI can develop the optimum treatment situations for further studies utilizing discrete inputs such as drug selection, dosing information, and nanomaterial characteristics. The amount of work required to build such a system is enormous